MetaCap

Aardvark Therapeutics (AARD) vs China Pharma (CPHI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

China Pharma (CPHI) has outperformed Aardvark Therapeutics (AARD) over the past year, losing 72.6% versus a loss of 90.2%. Aardvark Therapeutics is the larger company by market cap ($20.2 million vs $18.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AARD-90.15%CPHI-72.60%
+431%+158%-115%
Nov 21, 20251 yearNov 20, 2026
AARD-93.06%CPHI-80.07%
+29%-35%-99%
Feb 10, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AARD versus CPHI key metrics
MetricAARDCPHI
Share price$0.9226$0.4384
Market cap$20.20M$18.86M
1-day change-7.74%-13.00%
YTD return-92.97%-63.77%
1-year return-90.15%-72.60%
5-year return—-99.84%
EPS (TTM)$-3.33$-0.42
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$4.14M
Revenue growth (YoY)—-8.49%
Net income (latest FY)$-57.59M$-3.19M
Gross margin—-3.18%
Operating margin—-78.16%
Net margin—-76.91%
52-week high$16.60$19.19
52-week low$0.90$0.38
Distance from 52-week high-94.44%-97.72%
Analyst consensusbuy—
Avg. price target upside+1104.21%—
Average volume643.53K1.60M
Shares outstanding21.89M43.02M
Employees28215
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CPHI has outperformed AARD by 17.6 percentage points over the past year.

About Aardvark Therapeutics

AARD stock →

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc.

Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees

About China Pharma

CPHI stock →

China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China.

Health Care · Biotechnology: Pharmaceutical Preparations · 215 employees

AARD vs CPHI FAQ

Which is bigger, Aardvark Therapeutics or China Pharma?

Aardvark Therapeutics (AARD) is larger, with a market capitalization of $20.20M compared with $18.86M for China Pharma (CPHI).

Which stock has performed better over the past year, AARD or CPHI?

CPHI returned -72.60% over the past 12 months, compared with -90.15% for AARD (price return, excluding dividends). Past performance does not predict future results.

Are Aardvark Therapeutics and China Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons